Jodas Expoim Private Limited

Jodas Expoim Private Limited, established on September 4, 2006, is a private pharmaceutical company headquartered in Mulugu, Telangana, India. The company is registered under the Corporate Identification Number (CIN) U21001TG2006PTC110218. As of March 31, 2024, Jodas Expoim reported an authorized capital of ₹115.50 crore and a paid-up capital of ₹113.17 crore. The company employs approximately 737 professionals. Its manufacturing facility is located at Plot No.55 and 45, APIIC, Biotech Phase III, Karkapatla, Mulugu, Telangana, 502279.

Jodas Expoim operates a manufacturing plant situated in Mulugu, Telangana, India. The facility specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific production capacities are not publicly disclosed, the plant is designed to meet both domestic and international demand, adhering to stringent quality standards. The company's focus on oncology, contrast media, and critical care products underscores its commitment to specialized therapeutic areas.

The leadership team at Jodas Expoim Private Limited comprises:

• Satyendra Kumar Singh: Co-Founder and Managing Director, appointed on May 8, 2012.

• Jyoti Loomba: Co-Founder and Chief Managing Director, appointed on September 4, 2006.

• Shashi Shanker Parsad Singh: Co-Founder and Managing Director, appointed on November 29, 2008.

• Piyush Kumar Gupta: Director, appointed on January 11, 2012.

This team brings extensive experience in pharmaceutical manufacturing and international business development.

Jodas Expoim Private Limited has made significant strides in regulated markets, particularly in the United States, European Union, United Kingdom, Australia, and Japan. The company has successfully filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA), leading to the approval of several generic formulations. In the EU and UK, Jodas Expoim has obtained marketing authorizations for its products, ensuring compliance with the European Medicines Agency (EMA) and Medicines and Healthcare products Regulatory Agency (MHRA) standards. The company's adherence to Good Manufacturing Practice (GMP) guidelines has facilitated market access in Australia and Japan, where it has established distribution partnerships. These regulatory approvals underscore Jodas Expoim's commitment to quality and its capability to meet the stringent requirements of developed markets.

Jodas Expoim Private Limited has strategically expanded its presence in emerging markets across Africa, Latin America, and Southeast Asia. The company's products are registered in over 40 countries, facilitated by the World Health Organization (WHO) prequalification, which has been instrumental in gaining access to these regions. By collaborating with local partners, Jodas Expoim has established robust distribution networks, ensuring the availability of its high-quality medicines in underserved markets. This expansion aligns with the company's mission to make life-saving generics and biopharmaceutical products accessible globally.

Jodas Expoim Private Limited demonstrates a diversified geographic strategy, balancing its presence between developed and emerging markets. While it has a strong foothold in regulated markets such as the U.S., EU, UK, Australia, and Japan, the company has also made significant inroads into emerging markets in Africa, Latin America, and Southeast Asia. This strategic diversification mitigates concentration risk and positions Jodas Expoim to capitalize on growth opportunities across different regions. The company's focus on both high-volume generic products and specialized biopharmaceuticals allows it to cater to a broad spectrum of market needs, reinforcing its global presence.

Jodas Expoim Private Limited has achieved notable milestones with the U.S. Food and Drug Administration (FDA). The company has registered its manufacturing facility with the FDA, ensuring compliance with U.S. regulatory standards. It has successfully filed multiple Abbreviated New Drug Applications (ANDAs), leading to the approval of several generic formulations. These approvals reflect the company's commitment to quality and its capability to meet the stringent requirements of the U.S. market. Additionally, Jodas Expoim has maintained a clean inspection history, with no Form 483 observations or warning letters issued by the FDA, indicating consistent adherence to Good Manufacturing Practice (GMP) standards.

Jodas Expoim Private Limited has obtained Good Manufacturing Practice (GMP) certifications from both the World Health Organization (WHO) and the European Union (EU). The WHO prequalification has been instrumental in facilitating the company's entry into various international markets, particularly in Africa, Latin America, and Southeast Asia. The EU GMP certification underscores the company's adherence to high-quality manufacturing standards, enabling it to supply products to European markets. These certifications reflect Jodas Expoim's commitment to maintaining stringent quality controls and its capability to meet international regulatory requirements.

In India, Jodas Expoim Private Limited holds manufacturing licenses issued by the Central Drugs Standard Control Organisation (CDSCO), authorizing the production of pharmaceutical formulations. The company has obtained approvals from various state drug controllers, facilitating the distribution of its products across the country. Additionally, Jodas Expoim has secured export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), enabling the export of its products to international markets. These regulatory approvals demonstrate the company's compliance with Indian pharmaceutical regulations and its commitment to quality manufacturing practices.

As of March 28, 2026, there have been no publicly reported Form 483 observations, warning letters, or import alerts issued to Jodas Expoim Private Limited by the U.S. Food and Drug Administration (FDA). This indicates that the company has maintained a clean regulatory record in its interactions with the FDA. Similarly, there are no records of adverse regulatory actions from other agencies such as the European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), or the World Health Organization (WHO) concerning Jodas Expoim. This clean regulatory history reflects the company's commitment to adhering to international quality and compliance standards.

Jodas Expoim Private Limited operates in a competitive landscape, with several key players in the pharmaceutical industry offering similar products. In the oncology segment, companies such as Dr. Reddy's Laboratories, Cipla, and Sun Pharmaceutical Industries are prominent competitors. Jodas Expoim's focus on specialized formulations, including contrast media and critical care products, differentiates it from competitors who may have a broader product portfolio. The company's adherence to international quality standards, as evidenced by its WHO prequalification and EU GMP certifications, positions it favorably in the market. However, the competitive dynamics are influenced by factors such as pricing strategies, regulatory approvals, and market access, which can impact Jodas Expoim's market share and growth prospects.

Jodas Expoim Private Limited distinguishes itself through its specialized focus on oncology, contrast media, and critical care products. The company's commitment to innovation and continuous research and development enables it to offer high-quality generics and biopharmaceuticals. Its adherence to stringent quality standards, as demonstrated by certifications from the WHO and EU GMP, ensures the reliability and safety of its products. Additionally, Jodas Expoim's strategic expansion into emerging markets, facilitated by WHO prequalification, enhances its global reach and accessibility. These differentiators contribute to the company's competitive edge in the pharmaceutical industry.

Jodas Expoim Private Limited's current strategic direction emphasizes the development and distribution of generic pharmaceuticals and biopharmaceuticals, with a particular focus on oncology, contrast media, and critical care segments. The company's adherence to international quality standards and its expansion into both regulated and emerging markets reflect a balanced approach to growth and risk management. Looking ahead, Jodas Expoim aims to strengthen its position in existing markets while exploring new therapeutic areas and geographic regions. The company's commitment to innovation, regulatory compliance, and affordability positions it well for sustained growth and success in the global pharmaceutical industry.

Jodas Expoim Private Limited has demonstrated a strong track record in pharmaceutical manufacturing, with a focus on oncology, contrast media, and critical care products. The company's export volume of $24.4 million USD across 552 shipments indicates a consistent and reliable supply chain. Its adherence to international quality standards, as evidenced by certifications from the WHO and EU GMP, underscores the company's commitment to product excellence